Clover Biopharmaceuticals, a Chinese pre-revenue, clinical-stage biotech firm developing COVID-19 and other novel vaccines, has filed for an initial public offering (IPO) in Hong Kong.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
